18 January 2017 - Days before Donald Trump’s inauguration as President of the United States, there's already a reality-TV-sized dose of drama. 

For a case in point, zoom past the pyrotechnics around Trump’s cabinet nominees, currently being grilled in Congress, to the machinations around who will be named commissioner of the FDA.

Trump is unlikely to name an FDA commish until the conclusion of the nomination process for Rep. Tom Price, his pick to run the Department of Health and Human Services, because the FDA chief reports to HHS. But the inside track appears to go to Scott Gottlieb, a physician, cancer survivor and former FDA deputy commissioner who has been pushing the FDA to approve drugs faster and cut bureaucratic red tape for years.

Read Forbes magazine article